PT  - JOURNAL ARTICLE
AU  - Julkunen, Heli
AU  - Cichońska, Anna
AU  - Tiainen, Mika
AU  - Koskela, Harri
AU  - Nybo, Kristian
AU  - Mäkelä, Valtteri
AU  - Nokso-Koivisto, Jussi
AU  - Kristiansson, Kati
AU  - Perola, Markus
AU  - Salomaa, Veikko
AU  - Jousilahti, Pekka
AU  - Lundqvist, Annamari
AU  - Kangas, Antti J.
AU  - Soininen, Pasi
AU  - Barrett, Jeffrey C.
AU  - Würtz, Peter
TI  - Atlas of plasma nuclear magnetic resonance biomarkers for health and disease in 118,461 individuals from the UK Biobank
AID  - 10.1101/2022.06.13.22276332
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.06.13.22276332
4099  - http://medrxiv.org/content/early/2022/06/13/2022.06.13.22276332.short
4100  - http://medrxiv.org/content/early/2022/06/13/2022.06.13.22276332.full
AB  - Blood lipids and metabolites are both markers of current health and indicators of risk for future disease. Here, we describe plasma nuclear magnetic resonance (NMR) biomarker data for 118,461 participants in the UK Biobank, an open resource for public health research with extensive clinical and genomic data. The biomarkers cover 249 measures of lipoprotein lipids, fatty acids, and small molecules such as amino acids, ketones, and glycolysis metabolites. We provide a systematic atlas of associations of these biomarkers to prevalence, incidence, and mortality of over 700 common diseases. The results reveal a plethora of biomarker associations, including susceptibility to infectious diseases and risk for onset of various cancers, joint disorders, and mental health outcomes, indicating that abundant circulating lipids and metabolites are risk markers well beyond cardiometabolic diseases. Clustering analyses indicate similar biomarker association patterns across different types of diseases, such as liver diseases and polyneuropathies, suggesting latent systemic connectivity in the susceptibility to a diverse set of diseases. The release of NMR biomarker data at scale in the UK Biobank highlights the promise of metabolic profiling in large cohorts for public health research and translation.Address for Correspondence Peter Würtz, Nightingale Health, Mannerheimintie 164a, 00300 Helsinki, Finland. Peter.wurtz{at}nightingalehealth.comCompeting Interest StatementHJ, MT, HK, KN, VM, JN-K, AJK, PS, JB, and PW are employees of Nightingale Health Plc, and hold shares or stock options in Nightingale Health Plc. AC is former employee of Nightingale Health Plc. VS has received a honorarium for consulting from Sanofi and has ongoing research collaboration with Bayer Ltd outside this work.Funding StatementThe work was funded by Nightingale Health Plc.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval for UK Biobank was obtained from the North West Multi-Center Research Ethics Committee. The FINRISK and Health 2000 cohort studies were approved by the Coordinating Ethical Committee of the Helsinki and Uusimaa Hospital District, Finland. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe Nightingale Health NMR biomarker data have been released to the UK Biobank resource in spring 2021 (https://biobank.ndph.ox.ac.uk/showcase/label.cgi?id=220). The UK Biobank data are available for approved researchers through the UK Biobank data-access protocol. Data from FINRISK and Health 2000 cohorts may be accessed through THL Biobank (https://thl.fi/en/web/thl-biobank). As part of this publication, we provide access to all biomarker-disease summary statistics for academic use through an interactive webtool biomarker-atlas.nightingale.cloud. https://biobank.ndph.ox.ac.uk/showcase/label.cgi?id=220 https://thl.fi/en/web/thl-biobank https://biomarker-atlas.nightingale.cloud